Lexicon Pharmaceuticals, Inc.
LXRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $995.0M
$2.24
▼ -0.89%
P/E
-14.89
Mkt Cap
$995.0M
52-Wk Range
$1.05–$2.68
52-Week Range
$1.05 - $2.68
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 107.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary oral small molecule drug discovery platform
- Strategic partnerships with pharmaceutical industry leaders (Bristol-Myers Squibb, Genentech)
- Advanced clinical-stage candidates with significant market potential
- Experienced management team in drug development and commercialization
Bear Case
1 risk
- Average volatility.
Growth
Mild headwinds expected
Sotagliflozin regulatory approvals and market commercialization
Value
Trading at 0.0x sector peers — a discount despite the growth profile.
Momentum
Strong
+19.1% over 3m
Quality
Excellent
Emerging growth company (-29% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying LXRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.06 vs -$0.05 consensus (-19.4% surprise). Revenue of $692.0K vs $4.0M expected (-82.7%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-19.4%
Revenue trend · last 8Q
—
—
—
—
+710%
-79%
-21%
-98%
Q2 24
Q3 24
Q4 24
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$1.6M
$1.8M
$26.6M
$28.9M
$14.2M
$5.5M
$21.1M
$692.0K
Margins · last 8Q
Gross
94.4%
Operating
—
Profit
-4591.8%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · May 11, 2026
vs Industry
How LXRX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.